Descrizione del progetto
Un dispositivo a celle rivoluzionario per annunciare una rivoluzione nel campo medico
Le cellule staminali pluripotenti indotte (iPSC, induced pluripotent stem cell) sono in grado di trasformarsi in cellule umane di qualsiasi tipo in base alla necessità e possono essere trapiantate senza rischio di rigetto. Esse agevolano lo sviluppo di una fonte illimitata di qualsiasi tipologia di cellula umana richiesta per scopi terapeutici. Per tale ragione, tali cellule si dimostrano molto promettenti per il trattamento e la cura di una vasta gamma di problemi di salute. Ciononostante, i metodi esistenti frenano questo enorme potenziale. Il progetto AiPSC, finanziato dal CEI, si propone di sviluppare un dispositivo microfluidico basato sull’IA standardizzato, rapido ed efficiente in termini di costi allo scopo di consentire la produzione in serie di iPSC personalizzate per immunoterapie oncologiche adottive, trapianto di cellule staminali ematopoietiche e rigenerazione dei tessuti. Il progetto effettuerà inoltre una ricerca all’avanguardia nell’ambito della genomica a singola cellula e della bioinformatica sulle iPSC.
Obiettivo
Induced pluripotent stem cell (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy associated disease and defective tissues, is unprecedented in history. However, the current methodologies prohibit standardized production of person's own (autologous) iPSCs, hence rejection is taking place and the therapeutic promise is not fulfilled. Our consortium seeks to develop a new technology that will enable the mass production of personalized iPSCs for autologous adoptive cancer immunotherapies, hematopoietic stem cell transplantation, and tissue regeneration.
The consortium will for the first time create an artificial intelligence (AI) guided microfluidic device that standardizes the GMP production of autologous iPSCs fast and at a fraction of the current cost. Moreover, it will conduct cutting-edge single cell genomics and bioinformatics research of iPSC to identify clones of highest quality, and develop a database that will be the basis for AI software to select clones that meet clinical standards. The consortium comprises of experts in microfluidics engineering process automation for cell therapies, stem cell molecular biology and bioinformatics, GMP production, and AI modelling. The participating companies, startups, and universities are amongst the leading in Europe, and will promote the positions of female and early career participants from developed and developing European countries. The consortium aims to reach TRL3 prototype stage, and have created a concrete exploitation plan to develop the technology further for implementation in cancer therapy and regenerative medicine. Altogether, we propose to create revolutionary technology for low cost, fast, and standardized automated mass production of autologous iPSCs, which holds the potential to enable numerous new therapies and making them accessible to the public.
Campo scientifico
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesclinical medicinetransplantation
Programma(i)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Argomento(i)
Invito a presentare proposte
HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinatore
2333 CK LEIDEN
Paesi Bassi